Nektar Therapeutics Deferred Tax Liabilities, Leasing Arrangements
Nektar Therapeutics (NKTR) had Deferred Tax Liabilities, Leasing Arrangements of $1.83 million as of 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesLeasingArrangements · last filed 2025-03-14
- 2024-12-31: Deferred Tax Liabilities, Leasing Arrangements $1.83M.
- 2023-12-31: Deferred Tax Liabilities, Leasing Arrangements $3.82M.
- 2022-12-31: Deferred Tax Liabilities, Leasing Arrangements $11.34M.
- 2021-12-31: Deferred Tax Liabilities, Leasing Arrangements $27.20M.
| Period end | Deferred Tax Liabilities, Leasing Arrangements |
|---|---|
| 2024-12-31 | $1.83M 10-K · filed 2025-03-14 |
| 2023-12-31 | $3.82M 10-K · filed 2025-03-14 |
| 2022-12-31 | $11.34M 10-K · filed 2024-03-05 |
| 2021-12-31 | $27.20M 10-K · filed 2023-02-28 |
| 2020-12-31 | $29.71M 10-K · filed 2022-03-01 |
| 2019-12-31 | $31.72M 10-K · filed 2021-02-26 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |